Overview of Swedish Quality Registries Bertil Lindahl, Professor in Cardiology, Director of Uppsala...
-
Upload
william-francis -
Category
Documents
-
view
215 -
download
0
Embed Size (px)
Transcript of Overview of Swedish Quality Registries Bertil Lindahl, Professor in Cardiology, Director of Uppsala...

Overview of Swedish
Quality Registries
Bertil Lindahl, Bertil Lindahl,
Professor in Cardiology,Professor in Cardiology,
Director of Uppsala Clinical Director of Uppsala Clinical Research center.Research center.

Selective implementation with systematic follow-up
Clinical studies, including RCT.s
Systematic reviews / guidelines
Pre-clinicalresearch
Follow up of outcome and side-effects in clinical routine, nationally and locally
Implementation in clinical routine, nationally and locally
Knowledge based health care
Role for Quality Registries
Outcome research
Clopidogrel
Utbildnings-period
Resultat
Mätning innanprojektstart
Clopidogrel
Utbildnings-period
Resultat
Mätning innanprojektstart
ClopidogrelClopidogrel
Utbildnings-period
Utbildnings-period
ResultatResultat
Mätning innanprojektstart
Mätning innanprojektstart

”I am considered to be eccentric when I officially say that if the hospitals want to be certain to improve, they have to find out what results they have. They have to analyse their results to find strong and weak points. They have to compare their results with others.
These opinions will not be eccentric in a couple of years”.
Ernest Amory Codman MD 1917
Quality registry – no new idea

History of Swedish Quality Registries
Knäplastik; 1975
Höftplastikregistret; 1979
Kärlregistret; 1987
Oxygenregistret; 1987
Höftfrakturregistret; 1988
Pacemakerregistret; 1989
Registret för coronar angioplastik; 1990
Registret för aktiv uremivård; 1990

Swedish Quality Registries 2012
• 4 on level 1
• 20 on level 2
• 49 on level 3
• 27 candidates to become certified registries
73 registries covering a wide range of different interventions and diseases

Three different categories of registries
1. ”interventions”, eg. hip arthroplasty operation or heart surgery
2. ”diagnosis – based on an episode of a certain acute disease”, eg. myocardial infarction or stroke
3. ”diagnosis – chronic diseases”, eg. diabetes or rheumatoid arthritis

Currently ≈70 NationalQ. Registries
The
strategisk styrgrupp operativ beslutsgrupp.expertgrupp referensgrupper

Summary

National Quality RegistriesNational Quality Registries
UCRPatientrecord
Electronic PatientRecord
UCRData
Warehouse
UCRresearch db Publications
NationalHealthDataRegistries
Biobanking

SWEDE HEART
SCAAR
Data entry on line by the phyciansand nurses

SWEDE HEART
SCAAR
On-line reports


Proportion of AMI patients reaching LDL target level one year after AMI

The use of registries for
Research

•Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J. Am. Coll. Cardiol. 2010;55(13):1362-9.
•Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR . J. Am. Coll. Cardiol. 2010;56(6):470-5.
•Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction. Heart. 2010;96(6):453-9.
•Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Cardiovascular Interventions. Eur. Heart J. 2010;31(8):943-57.
•Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. BMJ. 2010 Jan 19;340:b5606.

Different aspects
•Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J. Am. Coll. Cardiol. 2010;55(13):1362-9.
•Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR . J. Am. Coll. Cardiol. 2010;56(6):470-5.
•Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction. Heart. 2010;96(6):453-9.
•Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Cardiovascular Interventions. Eur. Heart J. 2010;31(8):943-57.
•Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. BMJ. 2010 Jan 19;340:b5606.

Underutilization of quality
registries for health
economic studies



Costs were assigned using official statistical sources or market prices. Annual costs amounted to US$ 7666 per patient.


Thank you!